STOCK TITAN

Procaps Group, S.A. Ordinary Shares - PROC STOCK NEWS

Welcome to our dedicated page for Procaps Group, S.A. Ordinary Shares news (Ticker: PROC), a resource for investors and traders seeking the latest updates and insights on Procaps Group, S.A. Ordinary Shares stock.

Procaps Group, S.A. is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. With significant presence in over 50 countries across all five continents, Procaps Group has established itself as a key player in the healthcare industry. The company is headquartered in Latin America and has direct operations in 13 countries in the region.

Procaps Group engages in the development, manufacturing, and marketing of a wide range of products, including over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company operates through several segments, notably NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. Among these, the Procaps Colombia segment generates the highest revenue.

Procaps Group prides itself on its sustainable business model and employs over 5,000 collaborators globally. Their innovation-driven approach has resulted in numerous recent achievements and ongoing projects aimed at enhancing healthcare delivery and accessibility.

For investors looking to stay updated on Procaps Group's performance, the company consistently releases the latest news and updates, detailing their financial condition, new partnerships, product launches, and other significant developments. This ensures transparency and keeps shareholders well-informed.

Whether you're looking for in-depth information on the company or the latest updates on their stock performance, Procaps Group, S.A. remains a reliable source of pharmaceutical advancements and an important player in the global healthcare market.

Rhea-AI Summary

Procaps Group (NASDAQ: PROC) has announced a delay in filing its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, due to the need for additional time to review its financial statements related to a 2012 loan. The company expects to file the report before May 15, 2024, and will provide updates accordingly. Despite the delay, Procaps Group anticipates revenue and income growth for the year 2023 compared to 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.03%
Tags
none
-
Rhea-AI Summary
Procaps Group (NASDAQ: PROC) is exploring strategic alternatives to maximize shareholder value, with the appointment of a new CEO and the formation of a Strategic Committee. The company aims to accelerate growth and optimize shareholder value by considering various options with the help of BTG Pactual, a leading Latin American Investment Bank.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.05%
Tags
none
-
Rhea-AI Summary
Procaps Group, a leading LatAm healthcare and pharmaceutical conglomerate, has appointed a new CEO, Jose Vieira. The CEO's letter to shareholders emphasizes the commitment to transparency, innovation, and collaboration. The company's focus is on future growth, cash management, and profitability. Immediate actions will be taken to strengthen the company's financial position. The CEO plans to collaborate with the company to formulate a detailed strategic plan within the first 100 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
management
News
Rhea-AI Summary
Procaps Group, S.A. issued a press release addressing incorrect online voting instructions for the upcoming General Meeting of Shareholders. The Board of Directors has never recommended any vote in favor of the proposals to be voted on. The company is investigating the reason for the inaccurate statement and has requested a correction of all inaccurate statements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
-
Rhea-AI Summary
Procaps Group, S.A. (NASDAQ: PROC) reported a 5% increase in net revenues for 9M23 year-over-year on a constant currency basis, driven by 13% RX growth. The company's gross margin was 56% for 9M23, with an adjusted EBITDA of $51 million. The CEO announced a transition to Executive Chairman and a new CEO appointment. The company revised its full-year 2023 guidance, expecting a net revenues growth of approximately 6% on a constant currency basis and an adjusted EBITDA in the range of $77M - $82M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
-
Rhea-AI Summary
Procaps Group (NASDAQ: PROC) announced the transition of Ruben Minski from CEO to Executive Chairman of the Board, highlighting his leadership and achievements over the past four decades. The company has achieved significant milestones, including FDA certification for RX products and listing on Nasdaq in 2021. With a presence in 13 countries and a robust pipeline of over 100 products under development, Procaps is focused on long-term growth and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
management
Rhea-AI Summary
Procaps Group (PROC) and Genomma Lab Internacional (LABB) have announced a strategic agreement to develop, manufacture, and market five Softgel products within Latin America. Procaps will manufacture, and Genomma will market and distribute the products, leveraging Genomma’s marketing and distribution network to reach new customers. This collaboration aims to access new markets and introduce innovative oral delivery systems across a wide distribution network of independent and chain pharmacy retailers, wholesalers, and e-commerce channels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
Rhea-AI Summary
Procaps Group (PROC) Announces Strategic Leadership Transition with New CEO Jose Antonio Vieira
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.4%
Tags
management
-
Rhea-AI Summary
Procaps Group (NASDAQ: PROC) Postpones Earnings Conference Call for 3Q23 Results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.03%
Tags
Rhea-AI Summary
Procaps Group (NASDAQ: PROC) to host conference call on November 16, 2023, at 10:30 a.m. Eastern Time to discuss third quarter and nine months 2023 results. The leading integrated LatAm healthcare and pharmaceutical services company will report its financial results for the period ended September 30, 2023, after market closes on November 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.28%
Tags
conferences

FAQ

What is the current stock price of Procaps Group, S.A. Ordinary Shares (PROC)?

The current stock price of Procaps Group, S.A. Ordinary Shares (PROC) is $2.25 as of January 3, 2025.

What is the market cap of Procaps Group, S.A. Ordinary Shares (PROC)?

The market cap of Procaps Group, S.A. Ordinary Shares (PROC) is approximately 259.5M.

What does Procaps Group, S.A. specialize in?

Procaps Group, S.A. specializes in the development, manufacturing, and marketing of pharmaceutical and nutraceutical solutions, including OTC and prescription drugs, nutritional supplements, and high-potency clinical solutions.

In how many countries does Procaps Group, S.A. operate?

Procaps Group, S.A. has a direct presence in 13 countries in Latin America and its products reach over 50 countries worldwide.

What are the main business segments of Procaps Group, S.A.?

The main business segments of Procaps Group include NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics.

How many employees does Procaps Group, S.A. have?

Procaps Group, S.A. employs over 5,000 collaborators globally.

What types of products does Procaps Group, S.A. offer?

Procaps Group offers a range of products including over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions.

Which segment generates the most revenue for Procaps Group, S.A.?

The Procaps Colombia segment generates the most revenue for the company.

How does Procaps Group, S.A. ensure sustainability in its operations?

Procaps Group follows a sustainable business model and is committed to innovation-driven approaches to enhance healthcare delivery and accessibility.

Where is Procaps Group, S.A. headquartered?

Procaps Group, S.A. is headquartered in Latin America.

How can I stay updated on Procaps Group, S.A.'s latest news and developments?

You can stay updated by following the latest news releases and updates published by Procaps Group, S.A., which detail their financial condition, new partnerships, product launches, and other significant developments.

What is the ticker symbol for Procaps Group, S.A. on the stock market?

The ticker symbol for Procaps Group, S.A. on the stock market is PROC.
Procaps Group, S.A. Ordinary Shares

Nasdaq:PROC

PROC Rankings

PROC Stock Data

259.50M
19.15M
83.03%
2.93%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Luxembourg